tiprankstipranks
Advertisement
Advertisement

CH:GALD Stock Latest News

Galderma Buy Rating Reiterated as Strong Growth Outlook Drives Higher Revenue Forecasts; $260 Price Target Maintained
RatingsGalderma Buy Rating Reiterated as Strong Growth Outlook Drives Higher Revenue Forecasts; $260 Price Target Maintained
8d ago
Galderma: Solid Q1 Outperformance but Limited Upside Keeps Rating at Hold
PremiumRatings
Galderma: Solid Q1 Outperformance but Limited Upside Keeps Rating at Hold
12d ago
Galderma Group AG: Broad-Based Revenue Outperformance and Lower Execution Risk Support Buy Rating
PremiumRatings
Galderma Group AG: Broad-Based Revenue Outperformance and Lower Execution Risk Support Buy Rating
12d ago
Capitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating
PremiumRatings
Capitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating
25d ago
Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation
PremiumRatings
Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation
27d ago
Sustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating
PremiumRatingsSustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating
1M ago
Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating
Premium
Ratings
Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating
1M ago
Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation
Premium
Ratings
Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation
2M ago
Buy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside
PremiumRatings
Buy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside
2M ago
Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside
PremiumRatings
Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside
2M ago
Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects
PremiumRatings
Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects
3M ago
Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside
PremiumRatings
Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside
3M ago
Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections
PremiumRatingsGalderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections
5M ago
Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation
Premium
Ratings
Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation
5M ago
Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating
Premium
Ratings
Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating
6M ago
Galderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating
PremiumRatings
Galderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating
6M ago
Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook
PremiumRatings
Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook
6M ago
Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating
PremiumRatings
Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating
6M ago
Galderma Group AG: Buy Rating Affirmed Amid Tariff Challenges and Growth Prospects
PremiumRatings
Galderma Group AG: Buy Rating Affirmed Amid Tariff Challenges and Growth Prospects
7M ago
Strong Buy Rating for Galderma Group AG Driven by Nemluvio’s Market Performance and Medical Relevance
PremiumRatingsStrong Buy Rating for Galderma Group AG Driven by Nemluvio’s Market Performance and Medical Relevance
8M ago
Galderma Group AG: Strong First Half Performance and Upgraded Sales Outlook Justify Buy Rating
Premium
Ratings
Galderma Group AG: Strong First Half Performance and Upgraded Sales Outlook Justify Buy Rating
10M ago
Positive Outlook for Galderma Group AG Driven by Strong Nemluvio Prescription Growth and Upbeat Sales Forecast
Premium
Ratings
Positive Outlook for Galderma Group AG Driven by Strong Nemluvio Prescription Growth and Upbeat Sales Forecast
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >